MeMAGEN: A Phase IIa/IIb open‐label trial of memantine testing safety and tolerability in sickle cell patients
ABSTRACT Administration of memantine, an antagonist of the N‐methyl‐ d‐aspartate receptor, prevents Ca2+ overload and dehydration of red blood cells (RBCs) in patients with sickle cell disease (SCD). The objectives of the 1‐year dose‐escalation Phase IIa/IIb Memantine trial (MeMAGEN – NCT 03247218)...
Guardat en:
| Autors principals: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Wiley
2026-01-01
|
| Col·lecció: | HemaSphere |
| Accés en línia: | https://doi.org/10.1002/hem3.70278 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|